Bovilis Bovipast RSP

Product Information for Healthcare providers and Farmers

An aqueous suspension for subcutaneous injection. One dose (5 ml) of the vaccine contains at least 10^5.5 TCID₅₀ inactivated Bovine Respiratory Syncytial virus (strain EV 908) and at least 10^7.3 TCID₅₀ Parainfluenza-3- virus (strain SF-4 Reisinger), together with 9 x 10⁹ cells inactivated Mannheimia  haemolytica bacteria (serotype A1) propagated under conditions of iron restriction. Aluminium hydroxide and Quil A are included as adjuvants. Sodium timerfonate is included as a preservative.

For the active immunisation of cattle against 
– Parainfluenza3 virus (PI3 virus), to reduce infections. 
– Bovine Respiratory Syncytial Virus (BRSV) to reduce infection and clinical signs. 

– Mannheimia haemolytica serotype A1, to reduce infection, mortality, clinical signs, lung lesions and bacterial invasion of the lung caused by serotypes A1 and A6.

The double adjuvant in Bovilis Bovipast RSP, combined with inactivated bovine RSV, provides a significant step forward in RSV control – even in the face of MDA. The patented IRP (iron regulated protein) technology in Bovilis Bovipast RSP allows the vaccinated animal to mount a defence against Mannheimia haemolytica earlier in the cycle of bacterial attack than either traditional or leucotoxin vaccines. The same IRPs exist in other serotypes, including A6.

For uses, dosage, contra-indications and warnings please consult the Summary of Product Characteristics (SPC) or your veterinary supplier. Further information is available on request. Use medicines responsibly. 

Legal category 
POM(E)

Packaging Quantities 

50 ml bottle (10 doses) 

Bovilis Bovipast RSP Summary of Product Characteristics (SPC)

For Summary of Product Characteristics, first click on this link. Then scroll down to Documents section. Subsequently click on PDF version on line opposite Summary of Product Characteristics.